CD44+ HCC cell lines exhibit CSC activity in vitro; however, tocilizumab, a monoclonal antibody to the IL-6 receptor, can inhibit IL-6 function and downregulate TAM-mediated CD44+ cell activity, reducing the stemness of CD44+ cells [119]. This evidence concerns the gene CD44 and hepatocellular carcinoma.